Isaacs William B, Xu Jianfeng
Brady Urological Institute, Johns Hopkins University, School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
North Shore University Health System, Research Institute, Evanston, IL, USA.
Asian J Urol. 2019 Jan;6(1):3-9. doi: 10.1016/j.ajur.2018.10.001. Epub 2018 Nov 2.
Dramatic progress has been made in the area of germline genetics of prostate cancer (PCa) in the past decade. Both common and rare genetic variants with effects on risk ranging from barely detectable to outright practice-changing have been identified. For men with high risk PCa, the application of genetic testing for inherited pathogenic mutations is becoming standard of care. A major question exists about which additional populations of men to test, as men at all risk levels can potentially benefit by knowing their unique genetic profile of germline susceptibility variants. This article will provide a brief overview of some current issues in understanding inherited susceptibility for PCa.
在过去十年中，前列腺癌（PCa）的种系遗传学领域取得了显著进展。已经确定了对风险有影响的常见和罕见基因变异，其影响范围从几乎无法检测到彻底改变临床实践。对于高危前列腺癌男性患者，进行遗传性致病突变基因检测正成为标准治疗手段。关于对哪些其他男性群体进行检测存在一个主要问题，因为所有风险水平的男性都可能通过了解其独特的种系易感性变异基因谱而受益。本文将简要概述目前在理解前列腺癌遗传易感性方面的一些问题。
